L2 Asset Management LLC Purchases New Shares in Stryker Corporation $SYK

L2 Asset Management LLC purchased a new position in Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,084 shares of the medical technology company’s stock, valued at approximately $656,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Gables Capital Management Inc. purchased a new position in shares of Stryker in the second quarter worth approximately $25,000. Kilter Group LLC purchased a new stake in shares of Stryker in the 2nd quarter valued at approximately $25,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $26,000. Sankala Group LLC acquired a new position in Stryker in the 4th quarter worth approximately $26,000. Finally, Compass Financial Management LLC purchased a new position in Stryker during the 2nd quarter worth approximately $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 355,370 shares of company stock worth $119,447,201 in the last quarter. 4.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

SYK has been the topic of several recent analyst reports. Citigroup reissued a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. Finally, Raymond James Financial set a $370.00 price objective on Stryker in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Trading Up 1.0%

NYSE:SYK opened at $331.06 on Wednesday. The stock’s 50 day moving average price is $327.80 and its 200 day moving average price is $331.95. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a market capitalization of $126.98 billion, a P/E ratio of 34.31, a P/E/G ratio of 2.09 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter last year, the firm earned $3.13 EPS. Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.